Endo International PLC (ENDP): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Endo International ( ENDP) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.8%. By the end of trading, Endo International rose $0.72 (1.1%) to $66.86 on average volume. Throughout the day, 2,864,743 shares of Endo International exchanged hands as compared to its average daily volume of 2,475,400 shares. The stock ranged in a price between $64.82-$68.79 after having opened the day at $64.82 as compared to the previous trading day's close of $66.14. Other companies within the Drugs industry that increased today were: Idera Pharmaceuticals ( IDRA), up 17.8%, Trevena ( TRVN), up 11.4%, Actinium Pharmaceuticals ( ATNM), up 9.0% and CytRx Corporation ( CYTR), up 7.9%.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $7.7 billion and is part of the health care sector. Shares are down 2.0% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and weak operating cash flow.

On the negative front, Conatus Pharmaceuticals ( CNAT), down 15.6%, Tekmira Pharmaceuticals Corporation ( TKMR), down 14.5%, Exelixis ( EXEL), down 12.4% and Clovis Oncology ( CLVS), down 12.4% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists